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Abstract 
Review on Enchondroma, with data on clinics, and 
the genes involved. 
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Note 
Enchondroma is a common benign hyaline 
cartilaginous neoplasm that develops within the 
medullary cavity of bone. As the name suggests, it is 
located within the bone, either centrally (80% of 
cases) or eccentric (20% of cases). The most 
commonly affected bones in order of frequency are 
the phalanges of the hand, humerus, tibia and femur. 
. Enchondromas are very uncommon in flat bones 
such as the pelvis, ribs, scapula sternum or vertebrae. 
Enchondromas are mostly found in the diaphyseal or 
meta-diaphyseal region of the long bones while they 
are rarely observed in the epiphysis. . Thirty-five 
percent of enchondromas develop in the hand 
whereas its malignant counterpart is extremely rare 
at this location. In general, malignant transformation 
of enchondroma is extremely rare (overall risk <1% 
of cases). In rare instances, multiple enchondromas 
are found to occur in a syndrome 
(enchondromatosis). At gross specimen the 
enchondroma tissue looks white-grey and opalescent 
while yellow or red foci represent areas of 
calcification or ossification. 
Clinics and pathology 
Phenotype / cell stem origin 
Since many cartilaginous tumors develop from the 
medullar region of the bone, mesenchymal stem cells 
(MSCs) located in the bone marrow are currently 
considered the cell-of-origin for enchondroma. 
MSCs are stem cells that have the ability to 
differentiate into cells of the adipocytic, osteogenic 
and chondrogenic lineage. The initiating event of 
enchondroma development was identified after the 
observation that patients with multiple 
enchondromas are also at risk of developing other, 
unrelated, types of cancer like glioma and acute 
myeloid leukaemia and the finding that mutations in 
isocitrate dehydrogenase 1 or 2 (IDH1/2) are 
frequently found in these types of cancer. Therefore, 
cartilaginous tumors were also investigated for the 
occurrence of mutations in these genes. Indeed, in 
87% of enchondromas in patients with 
enchondromatosis and in 52% of solitary 
enchondromas mutations in IDH1 or -2 were found, 
pointing to this mutation as an early and crucial event 
in enchondroma development. Further evidence for 
a causative role of these mutations came from 
research showing increased chondrogenic and 
decreased osteogenic differentiation of MSCs upon 
treatment of MSCs from different donors with the 
oncometabolite D-2-hydroxyglutarate, the product 
of IDH mutations. Likewise, introduction of the 
most common IDH mutation found in enchondroma 
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into MSCs promoted chondrogenic differentiation, 
while inhibiting osteogenic differentiation. 
Epidemiology 
Enchondroma accounts for 10-25% of all benign 
tumours. Both sexes are equally affected and it 
shows a wide age range from 5-80 years, although 
the majority of patients present within the second to 
fifth decade of life. 
Clinics 
The differential diagnosis between enchondroma 
and low grade chondrosarcoma is difficult and is 
therefore based on a combination of clinical, 
radiological and histological parameters. Usually, 
enchondromas of the long bones are asymptomatic 
and detected incidentally after a fracture or bone 
scans for other reasons. In case of long bones, 
calcified enchondromas can be found. In contrast, 
enchondromas of the small bones of the hands and 
feet lack the calcification and may give palpable 
swellings, with or without pain. Enchondromas can 
be easily observed in radiographs since normal bone 
is replaced by mineralized or unmineralized hyaline 
cartilage. Radiographically, enchondromas are lytic 
lesions mostly in the center of the bone, can be 
mildly expansile with well defined, minimally 
thickened bony margins, along with intralesional 
calcification and diaphyseal expansion. There is 
evidence of cartilaginous matrix (rings and arcs or 
popcorn-like calcifications). 
Frontal radiograph of the right hand reveals a lytic lesion in 
the fourth proximal phalanx (yellow arrow) with subtle areas 
of calcified matrix within the lesion compatible withn an 
enchondroma. Picture from: http://www.radiologypics.com. 
Pathology 
Macroscopically, most enchondromas are <5 cm in 
size. The tissue is grey-white and opalescent.  
Gritty, yellow and red foci represent areas of 
calcification and ossification, respectively. 
Microscopically, enchondromas are hypocellular, 
avascular tumours with abundant hyaline cartilage 
matrix. The nuclei are small and round with 
condensed chromatin. Occasionally, binucleated 
cells without cytologic atypia are found.  
There is no mitotic activity. Myxoid matrix and 
endosteal erosion can be present in phalangeal 
tumors. There is often encasement (deposition of 
bone at the edges of the lobuli), while entrapment of 
preexisting host bone is absent and should be 
regarded a sign of progression to atypical 
cartilaginous tumour. More worrisome histological 
criteria such as increased cellularity, myxoid change, 
cytological atypia and nuclear hyperchromasia are 
only tolerated in case of 1) location in the small 
bones of the hands and feet, 2) in the context of 
enchondromatosis, 3) in young patients in which the 
growth plates are still open. 
 
Cartilaginous tumour with very low cellularity and 
abundance of chondroid matrix. Atypical cells and mitoses 
are absent. 
Treatment 
A wait-and-see policy is justified for asymptomatic 
lesions considered benign at radiography. Tumor 
growth can be determined clinically and by means of 
periodic radiographic examination. Biopsy can be 
done when asymptomatic lesions become large and 
symptomatic. Large or symptomatic tumours or 
borderline cases in which the distinction with low 
grade chondrosarcoma can not be made 
histologically nor radiographically can be treated 
surgically with margin improvement by means of 
phenol or cryosurgery. Recurrence of enchondroma 
is highly uncommon after curettage. 
Evolution 
Malignant transformation of solitary enchondroma is 
extremely rare (<1%). In the context of 
enchondromatosis (Ollier disease, Maffucci 
syndrome ) the risk of malignant transformation is 
increased up to 40%, depending on their location.  
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While enchondromas are most common at the 
phalangeal bones, chondrosarcoma of the phalanges 
is extremely rare. Local recurrence is uncommon, 
although occasionally an enchondroma will recur 
many years later, but rarely as an atypical 
cartilaginous tumor or low-grade chondrosarcoma. 
Prognosis 
Enchondroma is a benign lesion. Recurrence is 
highly uncommon after curettage. Progression 
towards malignancy is rare (5 cm) could indicate 
malignant transformation. Only those tumors that 
cause symptoms such as increase in size, pain or 
swelling should be further investigated and treated. 
Genetics 
Enchondroma is associated with heterozygous gain-
of-function mutations in the genes for IDH1 or IDH2 
(isocitrate dehydrogenase 1 (2q34) or 2 (15q26.1)). 
In 86% of enchondromas in enchondromatosis 
patients and in 52% of solitary enchondromas 
mutations in these genes have been found, as 
described above. IDH1 mutations are more frequent 
than IDH2 mutations in enchondroma, with R132C 
representing the most common mutation in 
cartilaginous tumors, followed by R132H.  
The normal function of IDH is in the TCA cycle, 
where it catalyzes the conversion of isocitrate into 
alpha-ketoglutarate. In the case of an IDH mutation, 
however, the enzyme converts alpha-ketoglutarate 
into D-2-hydroxyglutarate (D-2-HG), which is 
considered an oncometabolite. D-2-HG and alpha-
ketoglutarate are structurally similar, causing D-2-
HG to compete with alpha-ketoglutarate for binding 
to alpha-ketoglutarate-dependent enzymes. Most of 
these enzymes are involved in epigenetic regulation 
and examples include Jumonji-C domain-containing 
histone demethylases and the TET family of 5-
methylcytosine hydroxylases. Inhibition of these 
enzymes due to binding of D-2-HG results in DNA 
hypermethylation and histone modifications. Indeed, 
increased levels of D-2-HG and DNA 
hypermethylation have been found in enchondromas 
with IDH1/2 mutations. Another group of alfa-
ketoglutarate-dependent enzymes are the 
prolylhydroxylases, enzymes that promote 
degradation of HIF1A (hypoxia-inducible factor 1α). 
Indeed, IDH mutations, via an increase in D-2-HG, 
have been shown to lead to a stabilization of HIF1A, 
which in turn results in the stimulation of 
angiogenesis, an important feature of cancer.  
Interestingly, it was shown that while IDH1/2 
mutations may be crucial for initial enchondroma 
development, they are not essential anymore after 
progression towards chondrosarcoma has occurred. 
It is likely that other mutations occur, facilitating 
chondrosarcoma growth. 
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